We’re jacking up our price target on Amazon after its cloud unit surprises

We’re jacking up our price target on Amazon after its cloud unit surprises

Amazon shares surged Thursday in extended trading after the tech giant posted better-than-expected third-quarter results, driven by accelerated revenue growth from its cloud computing unit. The company’s outlook for the fourth quarter was also solid, easing investor fears that it was falling behind in the AI race. Revenue increased 13% year over year to $180.17…

Read More
China manufacturing slump deepens to 6-month low in October, as PMI misses estimates

China manufacturing slump deepens to 6-month low in October, as PMI misses estimates

Chinese-made automobiles and construction machinery are assembled and shipped for export at Yantai Port in Yantai City, Shandong Province, China, on October 21, 2025. Costfoto | Nurphoto | Getty Images China’s manufacturing activity in October contracted more than expected, shrinking to the lowest level in six months, an official survey showed on Friday, as trade…

Read More
Apple silences its critics with strong iPhone demand and blowout services revenue

Apple silences its critics with strong iPhone demand and blowout services revenue

Talk about a monster quarter. Apple delivered a great September quarter Thursday evening, even as iPhone supply was constrained by strong demand. The stock really got going after the company’s strong forecast for the holiday quarter. Revenue in Apple’s fiscal 2025 fourth quarter, which ended Sept. 27, rose 8% year over year to $102.47 billion,…

Read More
Breast cancer drug stock Olema could more than double from here, analysts say

Breast cancer drug stock Olema could more than double from here, analysts say

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up…

Read More